Copyright Reports & Markets. All rights reserved.

Global Cancer Antibody Drug Conjugates Market Insights and Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Cancer Antibody Drug Conjugates Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Cancer Antibody Drug Conjugates Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Cancer Antibody Drug Conjugates Market Size Growth Rate by Type
    • 1.4.2 First & Second Generation ADCs
    • 1.4.3 Third Generation ADCs
  • 1.5 Market by Application
    • 1.5.1 Global Cancer Antibody Drug Conjugates Market Size Growth Rate by Application
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Other
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Cancer Antibody Drug Conjugates Market Size, Estimates and Forecasts
    • 2.1.1 Global Cancer Antibody Drug Conjugates Revenue 2015-2026
    • 2.1.2 Global Cancer Antibody Drug Conjugates Sales 2015-2026
  • 2.2 Global Cancer Antibody Drug Conjugates, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Cancer Antibody Drug Conjugates Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Cancer Antibody Drug Conjugates Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Cancer Antibody Drug Conjugates Competitor Landscape by Players

  • 3.1 Cancer Antibody Drug Conjugates Sales by Manufacturers
    • 3.1.1 Cancer Antibody Drug Conjugates Sales by Manufacturers (2015-2020)
    • 3.1.2 Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Cancer Antibody Drug Conjugates Revenue by Manufacturers
    • 3.2.1 Cancer Antibody Drug Conjugates Revenue by Manufacturers (2015-2020)
    • 3.2.2 Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Cancer Antibody Drug Conjugates Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Cancer Antibody Drug Conjugates Revenue in 2019
    • 3.2.5 Global Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Cancer Antibody Drug Conjugates Price by Manufacturers
  • 3.4 Cancer Antibody Drug Conjugates Manufacturing Base Distribution, Product Types
    • 3.4.1 Cancer Antibody Drug Conjugates Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Cancer Antibody Drug Conjugates Product Type
    • 3.4.3 Date of International Manufacturers Enter into Cancer Antibody Drug Conjugates Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Cancer Antibody Drug Conjugates Market Size by Type (2015-2020)
    • 4.1.1 Global Cancer Antibody Drug Conjugates Sales by Type (2015-2020)
    • 4.1.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2015-2020)
    • 4.1.3 Cancer Antibody Drug Conjugates Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Cancer Antibody Drug Conjugates Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Type (2021-2026)
    • 4.2.3 Cancer Antibody Drug Conjugates Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Cancer Antibody Drug Conjugates Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Cancer Antibody Drug Conjugates Market Size by Application (2015-2020)
    • 5.1.1 Global Cancer Antibody Drug Conjugates Sales by Application (2015-2020)
    • 5.1.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2015-2020)
    • 5.1.3 Cancer Antibody Drug Conjugates Price by Application (2015-2020)
  • 5.2 Cancer Antibody Drug Conjugates Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Cancer Antibody Drug Conjugates Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Cancer Antibody Drug Conjugates by Country
    • 6.1.1 North America Cancer Antibody Drug Conjugates Sales by Country
    • 6.1.2 North America Cancer Antibody Drug Conjugates Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Type
  • 6.3 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Cancer Antibody Drug Conjugates by Country
    • 7.1.1 Europe Cancer Antibody Drug Conjugates Sales by Country
    • 7.1.2 Europe Cancer Antibody Drug Conjugates Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Type
  • 7.3 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Cancer Antibody Drug Conjugates by Region
    • 8.1.1 Asia Pacific Cancer Antibody Drug Conjugates Sales by Region
    • 8.1.2 Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Type
  • 8.3 Asia Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Cancer Antibody Drug Conjugates by Country
    • 9.1.1 Latin America Cancer Antibody Drug Conjugates Sales by Country
    • 9.1.2 Latin America Cancer Antibody Drug Conjugates Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Cancer Antibody Drug Conjugates Market Facts & Figures by Type
  • 9.3 Central & South America Cancer Antibody Drug Conjugates Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Cancer Antibody Drug Conjugates by Country
    • 10.1.1 Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country
    • 10.1.2 Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Type
  • 10.3 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Novartis
    • 11.1.1 Novartis Corporation Information
    • 11.1.2 Novartis Description and Business Overview
    • 11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Novartis Cancer Antibody Drug Conjugates Products Offered
    • 11.1.5 Novartis Related Developments
  • 11.2 Merck
    • 11.2.1 Merck Corporation Information
    • 11.2.2 Merck Description and Business Overview
    • 11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Merck Cancer Antibody Drug Conjugates Products Offered
    • 11.2.5 Merck Related Developments
  • 11.3 Roche
    • 11.3.1 Roche Corporation Information
    • 11.3.2 Roche Description and Business Overview
    • 11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Roche Cancer Antibody Drug Conjugates Products Offered
    • 11.3.5 Roche Related Developments
  • 11.4 AbbVie
    • 11.4.1 AbbVie Corporation Information
    • 11.4.2 AbbVie Description and Business Overview
    • 11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 AbbVie Cancer Antibody Drug Conjugates Products Offered
    • 11.4.5 AbbVie Related Developments
  • 11.5 UCB
    • 11.5.1 UCB Corporation Information
    • 11.5.2 UCB Description and Business Overview
    • 11.5.3 UCB Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 UCB Cancer Antibody Drug Conjugates Products Offered
    • 11.5.5 UCB Related Developments
  • 11.6 Bristol-Myers Squibb
    • 11.6.1 Bristol-Myers Squibb Corporation Information
    • 11.6.2 Bristol-Myers Squibb Description and Business Overview
    • 11.6.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Products Offered
    • 11.6.5 Bristol-Myers Squibb Related Developments
  • 11.7 Stem CentRx
    • 11.7.1 Stem CentRx Corporation Information
    • 11.7.2 Stem CentRx Description and Business Overview
    • 11.7.3 Stem CentRx Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Stem CentRx Cancer Antibody Drug Conjugates Products Offered
    • 11.7.5 Stem CentRx Related Developments
  • 11.8 Biogen Idec
    • 11.8.1 Biogen Idec Corporation Information
    • 11.8.2 Biogen Idec Description and Business Overview
    • 11.8.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Biogen Idec Cancer Antibody Drug Conjugates Products Offered
    • 11.8.5 Biogen Idec Related Developments
  • 11.9 Nordic Nanovector
    • 11.9.1 Nordic Nanovector Corporation Information
    • 11.9.2 Nordic Nanovector Description and Business Overview
    • 11.9.3 Nordic Nanovector Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Products Offered
    • 11.9.5 Nordic Nanovector Related Developments
  • 11.10 Millennium
    • 11.10.1 Millennium Corporation Information
    • 11.10.2 Millennium Description and Business Overview
    • 11.10.3 Millennium Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Millennium Cancer Antibody Drug Conjugates Products Offered
    • 11.10.5 Millennium Related Developments
  • 11.1 Novartis
    • 11.1.1 Novartis Corporation Information
    • 11.1.2 Novartis Description and Business Overview
    • 11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Novartis Cancer Antibody Drug Conjugates Products Offered
    • 11.1.5 Novartis Related Developments
  • 11.12 PDL BioPharma
    • 11.12.1 PDL BioPharma Corporation Information
    • 11.12.2 PDL BioPharma Description and Business Overview
    • 11.12.3 PDL BioPharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 PDL BioPharma Products Offered
    • 11.12.5 PDL BioPharma Related Developments
  • 11.13 Progenics Pharmaceuticals
    • 11.13.1 Progenics Pharmaceuticals Corporation Information
    • 11.13.2 Progenics Pharmaceuticals Description and Business Overview
    • 11.13.3 Progenics Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Progenics Pharmaceuticals Products Offered
    • 11.13.5 Progenics Pharmaceuticals Related Developments
  • 11.14 Seattle Genetics
    • 11.14.1 Seattle Genetics Corporation Information
    • 11.14.2 Seattle Genetics Description and Business Overview
    • 11.14.3 Seattle Genetics Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Seattle Genetics Products Offered
    • 11.14.5 Seattle Genetics Related Developments
  • 11.15 Viventia Biotechnologies
    • 11.15.1 Viventia Biotechnologies Corporation Information
    • 11.15.2 Viventia Biotechnologies Description and Business Overview
    • 11.15.3 Viventia Biotechnologies Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Viventia Biotechnologies Products Offered
    • 11.15.5 Viventia Biotechnologies Related Developments
  • 11.16 AbGenomics Corporation
    • 11.16.1 AbGenomics Corporation Corporation Information
    • 11.16.2 AbGenomics Corporation Description and Business Overview
    • 11.16.3 AbGenomics Corporation Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 AbGenomics Corporation Products Offered
    • 11.16.5 AbGenomics Corporation Related Developments
  • 11.17 Helix BioPharma
    • 11.17.1 Helix BioPharma Corporation Information
    • 11.17.2 Helix BioPharma Description and Business Overview
    • 11.17.3 Helix BioPharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.17.4 Helix BioPharma Products Offered
    • 11.17.5 Helix BioPharma Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Cancer Antibody Drug Conjugates Market Estimates and Projections by Region
    • 12.1.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Regions 2021-2026
  • 12.2 North America Cancer Antibody Drug Conjugates Market Size Forecast (2021-2026)
    • 12.2.1 North America: Cancer Antibody Drug Conjugates Sales Forecast (2021-2026)
    • 12.2.2 North America: Cancer Antibody Drug Conjugates Revenue Forecast (2021-2026)
    • 12.2.3 North America: Cancer Antibody Drug Conjugates Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Cancer Antibody Drug Conjugates Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Cancer Antibody Drug Conjugates Sales Forecast (2021-2026)
    • 12.3.2 Europe: Cancer Antibody Drug Conjugates Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Cancer Antibody Drug Conjugates Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Cancer Antibody Drug Conjugates Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Cancer Antibody Drug Conjugates Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Cancer Antibody Drug Conjugates Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Cancer Antibody Drug Conjugates Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Cancer Antibody Drug Conjugates Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Cancer Antibody Drug Conjugates Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Cancer Antibody Drug Conjugates Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Cancer Antibody Drug Conjugates Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Cancer Antibody Drug Conjugates Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Cancer Antibody Drug Conjugates Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Cancer Antibody Drug Conjugates Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Cancer Antibody Drug Conjugates Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Cancer Antibody Drug Conjugates Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Cancer Antibody Drug Conjugates Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Cancer Antibody Drug Conjugates market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Antibody Drug Conjugates market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Cancer Antibody Drug Conjugates market is segmented into
    First & Second Generation ADCs
    Third Generation ADCs

    Segment by Application, the Cancer Antibody Drug Conjugates market is segmented into
    Hospitals
    Clinics
    Other

    Regional and Country-level Analysis
    The Cancer Antibody Drug Conjugates market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Cancer Antibody Drug Conjugates market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Cancer Antibody Drug Conjugates Market Share Analysis
    Cancer Antibody Drug Conjugates market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Antibody Drug Conjugates business, the date to enter into the Cancer Antibody Drug Conjugates market, Cancer Antibody Drug Conjugates product introduction, recent developments, etc.

    The major vendors covered:
    Novartis
    Merck
    Roche
    AbbVie
    UCB
    Bristol-Myers Squibb
    Stem CentRx
    Biogen Idec
    Nordic Nanovector
    Millennium
    Biotest AG
    PDL BioPharma
    Progenics Pharmaceuticals
    Seattle Genetics
    Viventia Biotechnologies
    AbGenomics Corporation
    Helix BioPharma

    Buy now